Dr. Kevin Chang, MD, MS joins Austin Plastic Surgeon with extensive clinical and operational experience. Originally from St. Louis, Missouri and raised as a second generation Taiwanese American, he obtained his Doctorate of Medicine and Bachelor of Arts in Chemistry from the University of Missouri Kansas City School of Medicine. He then completed residency in Internal Medicine from 2004-2007 and had the honor of serving as chief resident and junior faculty from 2007-2008 at Brackenridge Hospital in Austin, which subsequently developed into the University of Texas at Austin Dell Medical School. After his clinical training he pursued a National Library of Medicine sponsored fellowship in Clinical Informatics at the Regenstrief Institute in Indianapolis from 2008-2010, where he also obtained a Master of Science in Health Informatics.
Ozempic is FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus, whereas Wegovy is FDA approved for chronic weight management as an adjunct to diet and exercise in patients with BMI > 30, or in patients with BMI > 27 and at least 1 weight-associated comorbidity such as hypertension or dyslipidemia. Usual Wegovy dosing for weight loss follows a monthly titration interval, beginning at 0.25mg weekly, then 0.5mg weekly, 1mg weekly, 1.7mg weekly, and a maximum of 2.4mg weekly as tolerated.
Ozempic is FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus, whereas Wegovy is FDA approved for chronic weight management as an adjunct to diet and exercise in patients with BMI > 30, or in patients with BMI > 27 and at least 1 weight-associated comorbidity such as hypertension or dyslipidemia. Thus if you meet these criteria and are trying to lose weight, you may be a good candidate for Wegovy.
Ozempic and Wegovy are both branded semaglutide products manufactured by Novo Nordisk. Ozempic is FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes mellitus, whereas Wegovy is FDA approved for chronic weight management as an adjunct to diet and exercise in patients with BMI & gt; 30, or in patients with BMI > 27 and at least 1 weight-associated comorbidity such as hypertension or dyslipidemia. Both are taken once weekly as a subcutaneous injection. Ozempic has a maximum dose of 2mg once weekly, Wegovy has a maximum dose of 2.4mg once weekly.
Ozempic face is a term describing changes to skin and underlying support structures that can occur with weight loss, which may result in wrinkles, skin looseness, or volume and unwanted appearance changes. While these negative changes do not necessarily happen to everyone experiencing weight loss with semaglutide, we recommend clinical regular monitoring and early preventive measures to minimize Ozempic face effects.
It should be noted that Ozempic, semaglutide, is approved to improve glycemic control in adults with Type 2 Diabetes mellitus, however weight loss has been seen as an added benefit. Wegovy, also semaglutide, is approved for chronic weight management as an adjunct to diet and exercise in patients meeting criteria. Some patients do gain weight back after stopping semaglutide when used for weight loss, however evidence generally points to better sustainability when treatment is paired with a commitment to diet and lifestyle modifications, physiologic adjustments with longer treatment duration, and allowance of habit psychology to take root for repeatable routines.
